Briefing Calendar IPOs Opportunities Companies Compare Analytics Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Secukinumab 300 mg, s.c. - Phase 3 | NVS Pipeline | CatalystAlert

Secukinumab 300 mg, s.c.

Phase 3

Novartis AG (NVS)

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

2w

NVS⭐Phase 3$274.7B

Secukinumab 300 mg, s.c. Phase 3 Results Expected

Secukinumab 300 mg, s.c.• Giant Cell Arteritis151

Jan 29

00%

Drug Information

Target Indication

Giant Cell Arteritis

Clinical Trial

Last updated: 1/16/2026

Developer

NVS

Novartis AG

Biotechnology•Europe•NYSE

Related Pipeline

FamciclovirPhase 3

Genital Herpes

Crizanlizumab (SEG101)Phase 3

Sickle Cell Disease (SCD)

DabrafenibPhase 3

Melanoma

secukinumab low dosePhase 3

Moderate to Severe Chronic Plaque-type Psoriasis

PimecrolimusPhase 3

Atopic Dermatitis

View full pipeline